TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Patient is between post kidney transplant day 3-7 and no requirement for dialysis~Exclusion:~* Patient is receiving kidney from HLA identical,living donor~* Patient is a multi-organ transplant recipient~* Patient is pregnant or lactating. Female patients of child bering potential must have a negative pregnancy test and agree to practice effective birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): early steroid cessation
- 2 (Type: EXPERIMENTAL): long-term maintenance steroids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with craniotomy for supratentorial tumors under general anesthesia~* American Society of Anaesthesiologists (ASA) 2 and stable ASA 3 patients~* Elective surgery~* Patients with Glasgow Coma Scale (GCS) 15/15~Exclusion Criteria:~* Patients with a history of allergy or hypersensitivity to tramadol.~* History of epilepsy or convulsions due to any reason.~* Chronic usage of analgesic drugs.~* Patients using monoamine oxidase inhibitors.~* Patients with clinical signs of raised ICP.~* Obesity (women with a body mass index \>35 kg/m2 or men with a body mass index \>42 kg/m2)~* Language barrier.~* Patients taking B-blockers or Ca channel blockers.~* Patients above 65 years of age ( Physiology difference)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tramadol (Type: EXPERIMENTAL): Injection Tramadol 100mg diluted in 10 cc syringe (10mg/ml) to be given as 1mg/kg or (1ml/10kg) via intravenous route, once, at the time of dura closure
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% Normal saline in 10 cc syringe,1ml/10kg via intravenous route, once at the time of dura closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Localized disease treated with surgery only~ * pT2, pT3, or pT4~ * pN0 or pNx~ * No clinical signs of progressive disease~* Prostate-specific antigen (PSA) meeting the following criteria:~  * PSA ≤ 0.1 ng/mL after prostatectomy~ * PSA ≥ 0.2 ng/mL and \< 2 ng/mL at study entry~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 10 years~* No other cancer in the past 5 years except for treated basal cell skin cancer~* No known pituitary gland adenoma~* No uncontrolled hypertension (i.e., blood pressure ≥ 160 mm Hg systolic and/or 90 mm Hg diastolic)~* No geographical, social, or psychological condition that would preclude study treatment~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior hormonal therapy~* No prior pelvic radiotherapy~* No prior surgical or chemical castration~* At least 6 months since surgery for biological recurrence~* No other concurrent anticancer therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- I (Type: ACTIVE_COMPARATOR): Exclusive Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
- II (Type: EXPERIMENTAL): Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) and GOSERELIN ACETATE in treating patients who have undergone surgery for recurent or refractory Prostate Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Male or female, age 18 years or older at the time of signing informed consent - Diagnosed with type 2 diabetes mellitus - HbA1c of 7.0-11.0 % (53 - 97 mmol/mol) (both inclusive) - Stable daily dose(s) including any of the following anti-diabetic drug(s) or combination regimens 90 days prior to the day of screening: a) Biguanides (metformin above or equal to 1500 mg or maximum tolerated dose documented in the subject's medical record). b) Sulphonylureas (above or equal to half of the maximum approved dose according to local label or maximum tolerated dose as documented in subject medical record). c) SGLT-2 inhibitors (above or equal to half of the maximum approved dose according to local label or maximum tolerated dose as documented in subject medical record) Exclusion Criteria: - Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. Family is defined as a first degree relative - History or presence of pancreatitis (acute or chronic) - History of diabetic ketoacidosis - Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening - Subjects presently classified as being in New York Heart Association (NYHA) Class IV - Planned coronary, carotid or peripheral artery revascularisation known on the day of screening - Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of below 30 ml/min/1.73 sqm as defined by KDIGO 2012 classification - Impaired liver function, defined as ALT above or equal to 2.5 times upper normal limit at screening - Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within the past 90 days prior to randomisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Half the study participants are randomised to receive semaglutide
- Liraglutide (Type: ACTIVE_COMPARATOR): Half the study participants are randomised to receive liraglutide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* neurological signs of AT~* patients in autonomous gait or helped by a support~* proven molecular diagnosis of AT~* Males and females aged \> 3 years~* Body weight \>15 kg~* Plasma levels of Lymphocytes CD4+/mm3 \> 500 (for patients aged 3-6 years) or \> 200 (older than 6 years)~* written IC to participate.~Exclusion Criteria:~* Current or previous neoplastic disease~* History of severe impairment of the immunological system~* Chronic conditions representing a contraindication to the use of steroid drugs~* Non compliance with the study request~* Any previous steroid assumption within 30 days before starting ERY-DEX~* Have any other significant disease that in the Investigator's opinion would exclude the patient from the trial~* Females of childbearing potential who were pregnant, breast-feeding or were not using adequate contraceptive methods

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ERY-DEX (Type: EXPERIMENTAL): Patients treated with monthly treatment of ERY-DEX (dexamethasone sodium phosphate encapsulated in autologous erythrocytes)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Good Schools Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
1. Inclusion Criteria:~   * Schools~     * in Luwero District, Uganda~    * more than 40 students registered in Primary 5~  * Participants~     * registered as a Primary 5, 6 or 7 pupil~    * any school staff member~2. Exclusion Criteria:~   * Schools~     -- existing program related to prevention of violence against children or school governance~  * Participants -- not able to understand consent and study procedures

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Good School Toolkit (Type: EXPERIMENTAL): Schools in the intervention arm will receive the Good Schools Toolkit materials and implementation support.
- Control (Type: NO_INTERVENTION): Schools in this arm will receive the Good Schools Toolkit materials and some implementation support after the end of the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years of age~2. Histologic proof of malignancy currently undergoing a course of RT (with or without chemotherapy) to a dose of ≥ 5000 cGy using 1.60 to 2.20 Gy per fraction. Note: At least one third of the oral cavity mucosa must be included in the radiation therapy fields.~3. ≥ 4 oral pain felt to be related to mucositis for which the patient wants relief as measured by the Numeric Measure of Oral Pain. Note: An oral exam confirming the presence of mucositis should be performed by the enrolling clinician in addition to patient feedback.~4. Ability to complete questionnaire(s) independently or with assistance~5. ECOG Performance Status 0, 1 or 2.~6. Provide informed written consent.~7. Willingness to return to enrolling institution for follow-up.~Exclusion Criteria:~1. Known allergy to doxepin, tricyclic antidepressants, or any known component of the drug formulation~2. Use of a tricyclic antidepressant or monoamine oxidase inhibitor within the 2 weeks prior to registration~3. Current untreated or unresolved oral candidiasis or oral HSV infection~4. Current untreated narrow angle glaucoma~5. Current untreated urinary retention ≤ 6 weeks prior to registration~6. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens~7. Any of the following because this study involves a study agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:~   * Pregnant women~  * Nursing women~  * Men or women of childbearing potential who are unwilling to employ adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive doxepin hydrochloride oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive placebo oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm I on day 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of Subcuticular Staples Versus Subcuticular Suture for Cesarean Section Skin Closure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Gestational age ≥ 24 weeks~* Scheduled cesarean section for any indication~* Pfannenstiel incision~* Singleton gestation~Exclusion criteria:~* Failure to consent~* Gestational age \< 24 weeks~* Vaginal delivery~* Intrauterine fetal death~* Multifetal gestation~* Suspected infection, i.e. chorioamnionitis~* BMI \> 50

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Subcuticular suture (Type: ACTIVE_COMPARATOR): Subcuticular suture has been used for many years to close skin incisions.
- Subcuticular staple (Type: ACTIVE_COMPARATOR): Subcuticular staples are a newer modality than suture, but are currently an accepted and widely used skin closure technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Augmenting Massed Prolonged Exposure With a Stellate Ganglion Block to Treat PTSD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Active duty or retired military service member (age 18- 65 years)~2. PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale (CAPS-5)~3. Able to speak and read English (due to standardization of outcome measures)~4. Defense Enrollment Eligibility Reporting System (DEERS)-eligible to receive care at Brooke Army Medical Center for the stellate ganglion block.~Exclusion Criteria:~1. Classification as high risk for suicide~2. Current serious mental health diagnosis (e.g., bipolar or psychosis)~3. Symptoms of moderate to severe substance (to include alcohol) use within the last 30 days~4. Pregnancy (i.e. positive pregnancy test at screening) or breastfeeding~5. Current anticoagulant use~6. History of bleeding disorder~7. Infection or mass at injection site~8. Myocardial infarction within 6 months of procedure~9. Pathologic bradycardia or irregularities of heart rate or rhythm;~10. Symptomatic hypotension~11. Phrenic or laryngeal nerve palsy~12. History of glaucoma~13. Uncontrolled seizure disorder~14. History of allergy to local anesthetics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Stellate Ganglion Block (Type: EXPERIMENTAL): One time administration of a stellate ganglion block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Airway Protective Mechanisms in PD (R01)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Between the ages of 45 and 85 years~2. Diagnosis of PD, Hoehn and Yahr stages I - IV, by a fellowship trained neurologist arriving at the diagnosis of PD by applying strict UK brain bank criteria (PD participants only)~Exclusion Criteria:~1. Neurological disorders other than PD (i.e., stroke, etc.)~2. Difficulty complying due to neuropsychological dysfunction (i.e., severe depression)~3. Allergy to capsaicin or hot peppers~4. History of head or neck cancer~5. History of smoking in the past 5 years~6. Any neurological disorder including PD (Healthy control group only)

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Study Arms:
- Healthy controls (Type: None): Men and women between the ages of 45 and 85 years without Parkinson's disease, or any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
- Parkinson's disease (Type: None): Men and women between the ages of 45 and 85 years with Parkinson's disease, and without any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Lung cancer patients who answer true to the following statements are eligible to join this clinical study.~* I have a confirmed diagnosis of locally advanced or metastatic non small cell lung cancer (Stage IIIb - IV)~* I have had 1st line anti-cancer therapy. Previous treatment with Avastin (bevacizumab) in first line NSCLC is allowed.~Exclusion Criteria:~Lung cancer patients who answer true to the following are NOT eligible to join this clinical study.~* I do not have non small cell lung cancer (NSCLC)~* I have received treatment with docetaxel (Taxotere). Prior treatment with paclitaxel is acceptable.~* I have received 2nd line anti-cancer therapy (For example, patients with previous 2nd line non small cell lung cancer (NSCLC) treatment with Tarceva (erlotinib, OSI-744), Alimta (pemetrexed) are not eligible)~* I have been treated with VEGFR-tyrosine kinase inhibitors (TKIs) (sunitinib, sorafenib, other VEGF TKIs). Previous treatment with Avastin (bevacizumab) in 1st line non small cell lung cancer is permitted.~* I have a history of uncontrolled irregular heartbeat~* I have a history of high blood pressure which has not been controlled with medication If you are unsure of the meaning of the inclusion and exclusion criteria above, please contact the call center number for help.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Docetaxel monotherapy
- 2 (Type: EXPERIMENTAL): Vandetanib + Docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes (diagnosed more than 12 months ago)~* HbA1c greater than 7.0 and less than 12.0% at screening~* Currently on any OAD in more than 3 months ago~* BMI (Body Mass Index) less than 35kg/m2~Exclusion Criteria:~* Previous treatment with insulin in more than 7 days within the last 3 months~* Uncontrolled treated/untreated hypertension (systolic blood pressure greater than 180mmHg and/or diastolic blood pressure less than 110mmHg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- insulin detemir (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life Impact of Nasal Airway Treatment With Aerin Medical Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Received nasal obstruction treatment in Aerin Study TP 258~Exclusion Criteria:~* Unwilling to participate in this long-term study

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Long-Term Study Subjects (Type: None): This cohort will consist of all subjects who were treated with the Vivaer Stylus in the 50-subject TP258 interventional study, who consent to continue to provide quality of life data.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female patients aged ≥40 with stable moderate to severe COPD (GOLD guidelines).~* Post-salbutamol (FEV1) \< 80% and ≥30% of predicted normal value and Post-salbutamol FEV1/FVC \< 70%.~* Current or ex-smokers of ≥10 pack-years.~Exclusion Criteria:~* Patients with no history or current diagnosis of asthma.~* No evidence of an exacerbation within 6 weeks prior to the screening visit.~* No evidence of clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities.~* No contraindication to use of anticholinergic drugs such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium bromide 200 μg bid (Type: EXPERIMENTAL): Aclidinium bromide 200 μg twice-daily via inhalation
- Aclidininum bromide 400 μg bid (Type: EXPERIMENTAL): Aclidinium bromide 400 μg twice-daily via inhalation
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete